JP2008512443A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512443A5
JP2008512443A5 JP2007530801A JP2007530801A JP2008512443A5 JP 2008512443 A5 JP2008512443 A5 JP 2008512443A5 JP 2007530801 A JP2007530801 A JP 2007530801A JP 2007530801 A JP2007530801 A JP 2007530801A JP 2008512443 A5 JP2008512443 A5 JP 2008512443A5
Authority
JP
Japan
Prior art keywords
vaccine
virus
influenza
culture
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007530801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/003266 external-priority patent/WO2006027698A1/en
Publication of JP2008512443A publication Critical patent/JP2008512443A/ja
Publication of JP2008512443A5 publication Critical patent/JP2008512443A5/ja
Withdrawn legal-status Critical Current

Links

JP2007530801A 2004-09-09 2005-09-09 インフルエンザワクチンに関連する潜在的医原性リスクの減少 Withdrawn JP2008512443A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04255471 2004-09-09
PCT/IB2005/003266 WO2006027698A1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with influenza vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011158471A Division JP2011207911A (ja) 2004-09-09 2011-07-19 インフルエンザワクチンに関連する潜在的医原性リスクの減少

Publications (2)

Publication Number Publication Date
JP2008512443A JP2008512443A (ja) 2008-04-24
JP2008512443A5 true JP2008512443A5 (cg-RX-API-DMAC7.html) 2011-11-24

Family

ID=35520177

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2007530801A Withdrawn JP2008512443A (ja) 2004-09-09 2005-09-09 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2011158471A Withdrawn JP2011207911A (ja) 2004-09-09 2011-07-19 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2011244904A Withdrawn JP2012025784A (ja) 2004-09-09 2011-11-08 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2013030624A Withdrawn JP2013100358A (ja) 2004-09-09 2013-02-20 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2015155818A Pending JP2015205929A (ja) 2004-09-09 2015-08-06 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2016230896A Withdrawn JP2017057209A (ja) 2004-09-09 2016-11-29 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2019146040A Pending JP2019210292A (ja) 2004-09-09 2019-08-08 インフルエンザワクチンに関連する潜在的医原性リスクの減少

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2011158471A Withdrawn JP2011207911A (ja) 2004-09-09 2011-07-19 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2011244904A Withdrawn JP2012025784A (ja) 2004-09-09 2011-11-08 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2013030624A Withdrawn JP2013100358A (ja) 2004-09-09 2013-02-20 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2015155818A Pending JP2015205929A (ja) 2004-09-09 2015-08-06 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2016230896A Withdrawn JP2017057209A (ja) 2004-09-09 2016-11-29 インフルエンザワクチンに関連する潜在的医原性リスクの減少
JP2019146040A Pending JP2019210292A (ja) 2004-09-09 2019-08-08 インフルエンザワクチンに関連する潜在的医原性リスクの減少

Country Status (15)

Country Link
US (6) US8119337B2 (cg-RX-API-DMAC7.html)
EP (5) EP2471551B1 (cg-RX-API-DMAC7.html)
JP (7) JP2008512443A (cg-RX-API-DMAC7.html)
AT (2) ATE488248T1 (cg-RX-API-DMAC7.html)
CA (2) CA2579859C (cg-RX-API-DMAC7.html)
CY (3) CY1111180T1 (cg-RX-API-DMAC7.html)
DE (3) DE602005024827D1 (cg-RX-API-DMAC7.html)
DK (4) DK2179744T3 (cg-RX-API-DMAC7.html)
ES (4) ES2357752T3 (cg-RX-API-DMAC7.html)
HR (4) HRP20100673T1 (cg-RX-API-DMAC7.html)
PL (4) PL2179744T3 (cg-RX-API-DMAC7.html)
PT (4) PT2578229E (cg-RX-API-DMAC7.html)
RS (3) RS51665B (cg-RX-API-DMAC7.html)
SI (4) SI2578229T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006027698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) * 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
WO2008059018A2 (en) * 2006-11-15 2008-05-22 Intervet International B.V. Vaccine for vaccinating felines and canines against influenza virus
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のh3抗原を含むインフルエンザワクチン
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2566958B1 (en) * 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Method for inactivating influenza virus
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
AU2011300402B2 (en) * 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
US9580761B2 (en) * 2011-02-25 2017-02-28 Novartis Ag Exogenous internal positive control
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
EP2791680B1 (en) * 2011-12-12 2015-12-09 Novartis AG Assay for influenza virus hemagglutinins
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたb型インフルエンザウイルス複製
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
JP2022514112A (ja) * 2018-10-15 2022-02-09 リジェネクスバイオ インコーポレイテッド 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
AU2020269164B2 (en) 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
JP2023511444A (ja) * 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたnaを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2022187230A2 (en) * 2021-03-01 2022-09-09 Iowa State University Research Foundation, Inc. Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
US20250381261A1 (en) 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193991A (en) * 1978-12-20 1980-03-18 Cornell Research Foundation, Inc. Canine parvovirus vaccine
EP0261955A3 (en) * 1986-09-26 1989-06-07 E.I. Du Pont De Nemours And Company Process for immobilization of dna
US6284492B1 (en) * 1988-02-26 2001-09-04 Large Scale Biology Corporation Recombinant animal viral nucleic acids
CA2054228A1 (en) 1990-10-30 1992-05-01 Masaharu Oki Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
JPH0813753B2 (ja) * 1992-05-22 1996-02-14 株式会社微生物化学研究所 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ3型ウイルス感染症、牛rsウイルス感染症および牛アデノ7型ウイルス感染症5種混合生ワクチン
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE4311580C1 (de) * 1993-04-12 1994-08-18 Werner Prof Dr Med Reutter Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JPH1175833A (ja) * 1997-06-23 1999-03-23 Chemo Sero Therapeut Res Inst トリレオウイルスの調製法
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP3795751B2 (ja) * 1997-12-11 2006-07-12 ユニバーシティ オブ サスカッチェワン ブタからの離乳後多全身系消耗症候群ウイルス
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN1678345B (zh) * 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
DK1520008T3 (da) * 2002-07-09 2012-10-15 Baxter Int Medium frit for dyreprotein til dyrkning af celler
JP3957188B2 (ja) * 2002-10-25 2007-08-15 ▲あき▼夫 友田 抗ウィルス剤
EP1596884A2 (en) 2003-01-30 2005-11-23 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
RS51665B (sr) * 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
SG182206A1 (en) 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants

Similar Documents

Publication Publication Date Title
JP2019210292A (ja) インフルエンザワクチンに関連する潜在的医原性リスクの減少
US20140315277A1 (en) Novel method
HK1172565A (en) Decreasing potential iatrogenic risks associated with influenza vaccines
HK1144374B (en) Decreasing potential latrogenic risks associated with influenza vaccines
HK1105364B (en) Decreasing potential iatrogenic risks associated with influenza vaccines